Efficacy and tolerability of valdoxan (agomelatin) in the treatment of mild and moderate depression caused by neurologic diseases (cerebrovascular disorders, neurocirculatory dystonia, chronic pain syndrome) were studied in a sample of 277 patients aged from 18 to 70 years (mean age 46.0±11.3 years), including 21.66% men and 76.53% women. Patients received valdoxan during 6 weeks. Symptoms of depression were arrested in 81.20% of patients. There was the decrease in signs of fatigability and the improvement of work effectiveness assessed by specific tests. Coefficient of mental stability reached normal values.